Having successfully closed a Series A financing for £28m, NodThera can now begin progressing molecules aimed at reducing chronic inflammation, known to be the root cause of a many diseases such as metabolic disorders, cancer and CNS diseases such as Alzheimer’s disease, the British biotech's chief science officer and acting CEO told Scrip.
"We'll use these funds to bring forward our preclinical drugs to target the inflammasome in inflammatory disease and they should...








